Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine adjunct to PCI for prevention of post-PCI adverse cardiovascular events
IRCT20200328046886N8Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Nov 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis, acute coronary syndrome (ACS) and myocardial infarction (MI) comparing Colchicine + PCI with Placebo + PCI (2 arms). Primary endpoints: Inflammatory markers after PCI and Cardiac and vascular events at 30 days. Started Nov 2025; status: completed.
02
Drugs
colchicine
03
Conditions
coronary arteriosclerosisacute coronary syndrome (ACS)myocardial infarction (MI)
Beyond the preview
Go deeper on IRCT20200328046886N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200328046886N8.